Author/Editor		Kovač, Damjan
Title		Zdravljenje hiperlipidemije z lovastatinom pri bolnikih s presajeno ledvico in ciklosporinsko imunosupresijo
Type		monografija
Place		Ljubljana
Publisher		Univerza v Ljubljani, Medicinska fakulteta
Publication year		1994
Volume		str. 56
Language		slo
Abstract		Atherosclerotic cardiovascular diseases are one of the major causes of death in patients with transplanted kidneys. Hyperlipidemia, especially elevated concentrations of total and LDL cholesterol, which is frequent in these patients, is important in the etiopathogenesis of atherosclerosis. Different drugs have been tried to counteract hyperlipidemia in patients with transplanted kidneys receiving Cy, but the results were very ambiguous and connected to side effects. Lovastatin is a very effective lipid-lowering drug, but it can cause damage to the skeletal muscles and liver in patients who concomitantly receive Cy. We wanted to evaluate the possibility of reaching the expected decrease of serum concentrations of total cholesterol, LDL cholesterol and triglycerides with lovastatin in daily doses of 20 mg, without causing signs of damage to the liver and to skeletal muscles which can be detected as well by quantitative electromyography in patients with transplanted kidney on cyclosporine immunosuppression who participated in this prospective clinical study. We wanted to evaluate the possibility of additional lowering the concentrations of total cholesterol, LDL cholesterol and triglycerides by increasing daily doses of lovastatin from 20 mg to 30 mg. We also wanted to evaluate the influence of lovastatin therapy on the serum concentrations of HDL cholesterol, Lp(a), Apo A-I and Apo B. Twelve patients with stable kidney function, who had a concentration of LDL cholesterol greater than 4.1 mmol/1 after a 3-month lipid-lowering diet participated in the study. All the patients were receiving Cy and corticosteroids and didn't have signs of damage to the skeletal muscles and liver at the beginning of study. In the first 3 months they received lovastatin in daily doses of 20 mg. After 3 months we increased the daily doses of lovastatin to 30 mg in 5 patients who still had a concentration of LDL cholesterol greater than 3.5 mmol/1. (Abstract truncated at 2000 characters.)
Descriptors		KIDNEY TRANSPLANTATION CYCLOSPORINE HYPERLIPIDEMIA LOVASTATIN CHOLESTEROL LIPOPROTEINS, LDL CHOLESTEROL TRIGLYCERIDES LIPOPROTEINS, HDL CHOLESTEROL APOLIPOPROTEINS ASPARTATE AMINOTRANSFERASE CREATINE KINASE MYOGLOBIN TREATMENT OUTCOME